Intensity Therapeutics, Inc.
NCM: INTSLive Quote
About Intensity Therapeutics, Inc.
Healthcare
Biotechnology
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
📊 Fundamental Analysis
Intensity Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -156.9%, which indicates that capital utilization is currently under pressure.
At a current price of $5.50, INTS currently trades near the bottom of its 52-week range (2%), indicating potential value or weakness (Range: $4.62 - $50.00).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$10.03M
Trailing P/E
--
Forward P/E
-1.38
Beta (5Y)
4.23
52W High
$50.00
52W Low
$4.62
Avg Volume
51K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App